Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Evolent Health, Inc.EVH · Entity 5492 | Director | June 13, 2018 | June 15, 2018 |
| Progyny, Inc.PGNY · Entity 4521 | Director | May 21, 2026 | May 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Evolent Health, Inc.
Report date June 13, 2018 · Filed June 15, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 21,284 |
Reported balance
After 2018-06-13 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-06-13 · Grant · Acquired 5,459 · Balance 21,284 F1: Represents restricted stock units granted to Dr. Payson pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2: Securities vest on the earlier of June 13, 2019 and the date of the company's 2019 annual meeting, subject to the reporting person's continued service on the vesting date. F3: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units granted to Dr. Payson pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.
F2: Securities vest on the earlier of June 13, 2019 and the date of the company's 2019 annual meeting, subject to the reporting person's continued service on the vesting date.
F3: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.
Progyny, Inc.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,349 |
Reported balance
After 2026-05-21 transaction · row 1
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 5,660 · Balance 12,349 F1: Represents the number of shares of Issuer common stock underlying restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs will vest on the earlier of (i) May 21, 2027 or (ii) the calendar day immediately preceding the date of the Issuer's first annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.69 · Expires 2036-05-20 | Direct | 3,203 |
Reported balance
After 2026-05-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-21 · Grant · Acquired 3,203 · Balance 3,203 F4: The option was issued to the Reporting Person in lieu of an annual cash retainer of $39,990 for board and committee service. The shares subject to the option will vest on the earlier of (i) May 21, 2027 or (ii) the calendar day immediately preceding the date of the Issuer's first annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.69 · Expires 2036-05-20 | Direct | 27,119 |
Reported balance
After 2026-05-21 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-21 · Grant · Acquired 27,119 · Balance 27,119 F5: The shares subject to the option will vest on the earlier of (i) May 21, 2027 or (ii) the calendar day immediately preceding the date of the Issuer's first annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on such date. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 331,363 |
Reported balance
Holding disclosure · report date 2026-05-21 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 331,363 F2: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 122,493 |
Reported balance
Holding disclosure · report date 2026-05-21 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 122,493 F3: The reportable securities are directly held by EVO Eagle, LLC. The Reporting Person shares voting and dispositive power over the securities. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of Issuer common stock underlying restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs will vest on the earlier of (i) May 21, 2027 or (ii) the calendar day immediately preceding the date of the Issuer's first annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on such date.
F2: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust.
F3: The reportable securities are directly held by EVO Eagle, LLC. The Reporting Person shares voting and dispositive power over the securities.
F4: The option was issued to the Reporting Person in lieu of an annual cash retainer of $39,990 for board and committee service. The shares subject to the option will vest on the earlier of (i) May 21, 2027 or (ii) the calendar day immediately preceding the date of the Issuer's first annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on such date.
F5: The shares subject to the option will vest on the earlier of (i) May 21, 2027 or (ii) the calendar day immediately preceding the date of the Issuer's first annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Apria, Inc.
Report date March 29, 2022 · Filed March 29, 2022
Section 16 reporting ended · disclosed 2022-03-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-03-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-29 · Disposition to issuer · Disposed 5,059 · Balance 0 F2: Represents a contingent right to receive one share of the Issuer's Common Stock payable in Common Stock, cash or a combination thereof at the discretion of the Issuer's Compensation Committee. F1: On March 29, 2022, Owens & Minor, Inc. ("Owens & Minor") acquired the Issuer pursuant to a certain Agreement and Plan of Merger, dated as of January 7, 2022 (the "Merger Agreement"), by and among the Issuer, Owens & Minor and StoneOak Merger Sub Inc., an indirect, wholly owned subsidiary of Owens & Minor ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as an indirect, wholly owned subsidiary of Owens & Minor. At the effective time of the Merger, each issued and outstanding share of the Issuer's Common Stock (other than certain excluded shares) automatically converted into the right to receive $37.50 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Pursuant to the Merger Agreement, each restricted stock unit ("RSU") became fully vested and cancelled and entitled the holder to receive an amount of cash, without interest and subject to deduction for any required tax withholding, equal to the number of shares of Common Stock subject to such RSU, immediately prior to the effective time of the Merger, multiplied by the Merger Consideration. F4: Represents RSUs granted in 2021, which were originally scheduled to vest on the earlier of (i) June 10, 2022 and (ii) the first regularly scheduled annual meeting of the stockholders of the Company following the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 29, 2022, Owens & Minor, Inc. ("Owens & Minor") acquired the Issuer pursuant to a certain Agreement and Plan of Merger, dated as of January 7, 2022 (the "Merger Agreement"), by and among the Issuer, Owens & Minor and StoneOak Merger Sub Inc., an indirect, wholly owned subsidiary of Owens & Minor ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as an indirect, wholly owned subsidiary of Owens & Minor. At the effective time of the Merger, each issued and outstanding share of the Issuer's Common Stock (other than certain excluded shares) automatically converted into the right to receive $37.50 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax.
F2: Represents a contingent right to receive one share of the Issuer's Common Stock payable in Common Stock, cash or a combination thereof at the discretion of the Issuer's Compensation Committee.
F3: Pursuant to the Merger Agreement, each restricted stock unit ("RSU") became fully vested and cancelled and entitled the holder to receive an amount of cash, without interest and subject to deduction for any required tax withholding, equal to the number of shares of Common Stock subject to such RSU, immediately prior to the effective time of the Merger, multiplied by the Merger Consideration.
F4: Represents RSUs granted in 2021, which were originally scheduled to vest on the earlier of (i) June 10, 2022 and (ii) the first regularly scheduled annual meeting of the stockholders of the Company following the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 10, 2022 Filed Mar 11, 2022 21:33 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 2,395 | $44.84 | $107,391.80 |
DisclosureSEC source: 0001179110-22-002146 · edgar.xml · nonDerivative · entry 5 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 322,426 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5),(6), (7) and (8). F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.68 to $45.28, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| March 10, 2022 Filed Mar 11, 2022 21:33 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 5,935 | $44.20 | $262,327.00 |
DisclosureSEC source: 0001179110-22-002146 · edgar.xml · nonDerivative · entry 4 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 324,821 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5),(6), (7) and (8). F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.67 to $44.65, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 21:33 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 200 | $46.01 | $9,202.00 |
DisclosureSEC source: 0001179110-22-002146 · edgar.xml · nonDerivative · entry 3 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 330,756 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5),(6), (7) and (8). F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.97 to $46.03, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 21:33 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 7,860 | $45.58 | $358,258.80 |
DisclosureSEC source: 0001179110-22-002146 · edgar.xml · nonDerivative · entry 2 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See attached Disclosed balance after: 330,956 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5),(6), (7) and (8). F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.96 to $45.91, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 21:33 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 450 | $43.96 | $19,782.00 |
DisclosureSEC source: 0001179110-22-002146 · edgar.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 338,636 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.84 to $44.14, inclusive. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5),(6), (7) and (8). F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| March 03, 2022 Filed Mar 5, 2022 02:35 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 800 | $44.12 | $35,296.00 |
DisclosureSEC source: 0001104659-22-030786 · tm228503-3_4seq1.xml · nonDerivative · entry 5 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 339,086 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6),(7) and (8). F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.01 to $44.25, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| March 03, 2022 Filed Mar 5, 2022 02:35 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 7,530 | $43.62 | $328,458.60 |
DisclosureSEC source: 0001104659-22-030786 · tm228503-3_4seq1.xml · nonDerivative · entry 4 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 339,886 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6),(7) and (8). F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.975 to $43.95, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| March 02, 2022 Filed Mar 5, 2022 02:35 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 4,614 | $44.60 | $205,784.40 |
DisclosureSEC source: 0001104659-22-030786 · tm228503-3_4seq1.xml · nonDerivative · entry 3 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 347,416 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6),(7) and (8). F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.34 to $44.89, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| March 02, 2022 Filed Mar 5, 2022 02:35 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 1,800 | $43.81 | $78,858.00 |
DisclosureSEC source: 0001104659-22-030786 · tm228503-3_4seq1.xml · nonDerivative · entry 2 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 352,030 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6),(7) and (8). F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.25 to $44.225, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| March 02, 2022 Filed Mar 5, 2022 02:35 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 1,916 | $42.74 | $81,889.84 |
DisclosureSEC source: 0001104659-22-030786 · tm228503-3_4seq1.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 353,830 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.24 to $43.215, inclusive. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6),(7) and (8). F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 21:31 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 4,910 | $36.04 | $176,956.40 |
DisclosureSEC source: 0001179110-22-001661 · edgar.xml · nonDerivative · entry 6 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 355,746 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6),(7), (8) and (9). F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $36.695, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 21:31 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 1,720 | $34.48 | $59,305.60 |
DisclosureSEC source: 0001179110-22-001661 · edgar.xml · nonDerivative · entry 5 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 360,656 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6),(7), (8) and (9). F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.99 to $34.945, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 21:31 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 1,700 | $33.50 | $56,950.00 |
DisclosureSEC source: 0001179110-22-001661 · edgar.xml · nonDerivative · entry 4 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 362,376 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6),(7), (8) and (9). F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.95 to $33.9, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 21:31 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 300 | $36.87 | $11,061.00 |
DisclosureSEC source: 0001179110-22-001661 · edgar.xml · nonDerivative · entry 3 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 364,076 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6),(7), (8) and (9). F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.72 to $37.15, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 21:31 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 2,400 | $35.92 | $86,208.00 |
DisclosureSEC source: 0001179110-22-001661 · edgar.xml · nonDerivative · entry 2 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 364,376 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6),(7), (8) and (9). F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.575 to $36.38, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 21:31 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 5,630 | $34.95 | $196,768.50 |
DisclosureSEC source: 0001179110-22-001661 · edgar.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 366,776 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.55 to $35.54, inclusive. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6),(7), (8) and (9). F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| February 17, 2022 Filed Feb 18, 2022 21:46 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 2,900 | $39.83 | $115,507.00 |
DisclosureSEC source: 0001179110-22-001427 · edgar.xml · nonDerivative · entry 4 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 372,406 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6) and (7). F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.645 to $40.21, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| February 17, 2022 Filed Feb 18, 2022 21:46 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 5,430 | $39.17 | $212,693.10 |
DisclosureSEC source: 0001179110-22-001427 · edgar.xml · nonDerivative · entry 3 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 375,306 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6) and (7). F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.65 to $39.64, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 21:46 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 3,774 | $40.79 | $153,941.46 |
DisclosureSEC source: 0001179110-22-001427 · edgar.xml · nonDerivative · entry 2 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 380,736 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6) and (7). F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.56 to $41.01, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 21:46 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 4,556 | $40.25 | $183,379.00 |
DisclosureSEC source: 0001179110-22-001427 · edgar.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 384,510 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.56 to $40.55, inclusive. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6) and (7). F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| February 10, 2022 Filed Feb 11, 2022 21:31 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 5,530 | $40.93 | $226,342.90 |
DisclosureSEC source: 0001179110-22-001102 · edgar.xml · nonDerivative · entry 4 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 389,066 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6) and (7). F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.78 to $41.26, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| February 10, 2022 Filed Feb 11, 2022 21:31 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 2,800 | $40.50 | $113,400.00 |
DisclosureSEC source: 0001179110-22-001102 · edgar.xml · nonDerivative · entry 3 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 394,596 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6) and (7). F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.78 to $40.77, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 21:31 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 3,002 | $40.65 | $122,031.30 |
DisclosureSEC source: 0001179110-22-001102 · edgar.xml · nonDerivative · entry 2 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 397,396 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6) and (7). F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.54 to $40.77, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 21:31 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 5,328 | $40.18 | $214,079.04 |
DisclosureSEC source: 0001179110-22-001102 · edgar.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 400,398 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.54 to $40.53, inclusive. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6) and (7). F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| February 03, 2022 Filed Feb 4, 2022 22:00 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 1,800 | $38.37 | $69,066.00 |
DisclosureSEC source: 0001179110-22-000872 · edgar.xml · nonDerivative · entry 4 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 405,726 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6) and (7). F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.10 to $38.77, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| February 03, 2022 Filed Feb 4, 2022 22:00 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 6,530 | $37.42 | $244,352.60 |
DisclosureSEC source: 0001179110-22-000872 · edgar.xml · nonDerivative · entry 3 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 407,526 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6) and (7). F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.08 to $38.07, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 22:00 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 500 | $40.15 | $20,075.00 |
DisclosureSEC source: 0001179110-22-000872 · edgar.xml · nonDerivative · entry 2 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 414,056 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6) and (7). F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.91. to $40.40, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 22:00 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 7,830 | $39.24 | $307,249.20 |
DisclosureSEC source: 0001179110-22-000872 · edgar.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 414,556 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.80 to $39.67, inclusive. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6) and (7). F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| January 27, 2022 Filed Jan 28, 2022 21:16 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 300 | $37.86 | $11,358.00 |
DisclosureSEC source: 0001179110-22-000648 · edgar.xml · nonDerivative · entry 5 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 422,386 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7) and (8). F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.84 to $37.865, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| January 27, 2022 Filed Jan 28, 2022 21:16 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 8,030 | $37.32 | $299,679.60 |
DisclosureSEC source: 0001179110-22-000648 · edgar.xml · nonDerivative · entry 4 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 422,686 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7) and (8). F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.82 to $37.81, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 21:16 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 3,300 | $39.44 | $130,152.00 |
DisclosureSEC source: 0001179110-22-000648 · edgar.xml · nonDerivative · entry 3 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 430,716 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7) and (8). F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.035 to $39.97, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 21:16 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 2,400 | $38.58 | $92,592.00 |
DisclosureSEC source: 0001179110-22-000648 · edgar.xml · nonDerivative · entry 2 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 434,016 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7) and (8). F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.955 to $38.895, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 21:16 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 2,630 | $37.13 | $97,651.90 |
DisclosureSEC source: 0001179110-22-000648 · edgar.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 436,416 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.76 to $37.52, inclusive. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7) and (8). F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| January 20, 2022 Filed Jan 21, 2022 22:00 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 2,085 | $40.28 | $83,983.80 |
DisclosureSEC source: 0001179110-22-000557 · edgar.xml · nonDerivative · entry 6 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 439,046 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8) and (9). F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.105 to $40.50, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| January 20, 2022 Filed Jan 21, 2022 22:00 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 3,731 | $39.55 | $147,561.05 |
DisclosureSEC source: 0001179110-22-000557 · edgar.xml · nonDerivative · entry 5 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footote Disclosed balance after: 441,131 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8) and (9). F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.10 to $40.09, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| January 20, 2022 Filed Jan 21, 2022 22:00 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 2,514 | $38.32 | $96,336.48 |
DisclosureSEC source: 0001179110-22-000557 · edgar.xml · nonDerivative · entry 4 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 444,862 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8) and (9). F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.10 to $38.73, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 22:00 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 500 | $40.37 | $20,185.00 |
DisclosureSEC source: 0001179110-22-000557 · edgar.xml · nonDerivative · entry 3 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 447,376 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8) and (9). F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.26 to $40.45, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 22:00 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 3,985 | $39.56 | $157,646.60 |
DisclosureSEC source: 0001179110-22-000557 · edgar.xml · nonDerivative · entry 2 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 447,876 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8) and (9). F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.22 to $40.16, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 22:00 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 3,845 | $38.68 | $148,724.60 |
DisclosureSEC source: 0001179110-22-000557 · edgar.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 451,861 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.21 to $39.17, inclusive. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8) and (9). F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| January 13, 2022 Filed Jan 14, 2022 22:42 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 100 | $45.75 | $4,575.00 |
DisclosureSEC source: 0001179110-22-000511 · edgar.xml · nonDerivative · entry 6 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 455,706 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| January 13, 2022 Filed Jan 14, 2022 22:42 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 3,714 | $44.87 | $166,647.18 |
DisclosureSEC source: 0001179110-22-000511 · edgar.xml · nonDerivative · entry 5 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 455,806 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), and (8). F8 · price: ) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.56 to $45.39, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| January 13, 2022 Filed Jan 14, 2022 22:42 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 4,516 | $44.05 | $198,929.80 |
DisclosureSEC source: 0001179110-22-000511 · edgar.xml · nonDerivative · entry 4 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 459,520 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), and (8). F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.55 to $44.54, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| January 12, 2022 Filed Jan 14, 2022 22:42 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 633 | $47.65 | $30,162.45 |
DisclosureSEC source: 0001179110-22-000511 · edgar.xml · nonDerivative · entry 3 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 464,036 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), and (8). F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.49 to $47.745, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| January 12, 2022 Filed Jan 14, 2022 22:42 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 4,896 | $46.94 | $229,818.24 |
DisclosureSEC source: 0001179110-22-000511 · edgar.xml · nonDerivative · entry 2 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See attached Disclosed balance after: 464,669 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), and (8). F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.46 to $47.45, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| January 12, 2022 Filed Jan 14, 2022 22:42 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 2,801 | $45.53 | $127,529.53 |
DisclosureSEC source: 0001179110-22-000511 · edgar.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 469,565 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.26 to $46.05, inclusive. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), and (8). F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| January 06, 2022 Filed Jan 7, 2022 22:52 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 6,730 | $46.22 | $311,060.60 |
DisclosureSEC source: 0001179110-22-000342 · edgar.xml · nonDerivative · entry 5 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 472,366 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), and (8). F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.67 to $46.64, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| January 06, 2022 Filed Jan 7, 2022 22:52 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 1,600 | $45.18 | $72,288.00 |
DisclosureSEC source: 0001179110-22-000342 · edgar.xml · nonDerivative · entry 4 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 479,096 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), and (8). F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.66 to $45.61, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 22:52 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 300 | $48.06 | $14,418.00 |
DisclosureSEC source: 0001179110-22-000342 · edgar.xml · nonDerivative · entry 3 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 480,696 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), and (8). F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.95 to $48.18, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 22:52 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 4,600 | $47.54 | $218,684.00 |
DisclosureSEC source: 0001179110-22-000342 · edgar.xml · nonDerivative · entry 2 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 480,996 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), and (8). F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.95 to $47.85, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 22:52 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 3,430 | $46.15 | $158,294.50 |
DisclosureSEC source: 0001179110-22-000342 · edgar.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 485,596 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.945 to $46.87, inclusive. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), and (8). F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.